Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Gyre Therapeutics, Inc. Common Stock

GYRE

Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Last trade $4.53
Day change +$0.135 (+3.08%)
Day range $4.33 – $4.69
Volume 103,792
Market cap $480M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$480.49M
Price / earnings
—
Price / book
4.45×
Price / sales
3.95×
EV / sales
3.6×
EV / EBITDA
-20.13×

Profitability

Earnings per share
-$0.24
Return on assets
-12.98%
Return on equity
-24.2%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
4.32×
Quick ratio
3.89×
Cash ratio
1.46×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$24.72M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for GYRE, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$32.93M$29.11M$22.52M$37.2M$32.69M$29.73M$22.06M$27.87M
Cost of revenue$1.95M$2.21M$1.23M$1.74M$1.63M$1.15M$894K$1.18M
Gross profit$30.99M$26.9M$21.29M$35.45M$31.07M$28.58M$21.16M$26.7M
Selling, general and administrative$23.95M$21.62M$21.36M$30.52M$21.78M$22.47M$15.8M$22.32M
Research and development$8.51M$19.14M$6.74M$4.82M$7.8M$8.35M$3.1M$3.71M
Total operating expenses$32.51M$41.26M$30.65M$35.33M$29.57M$30.82M$18.89M$26.03M
Operating income-$1.52M-$14.36M-$9.36M$120K$1.49M-$2.24M$2.27M$663K
Interest expense$0$0$0$1.75M$0$0$0$1.55M
Income before taxes-$1.75M-$14.43M-$9.24M-$66K$2.52M-$1.58M$4.64M$772K
Income taxes$733K-$164K$621K$1.3M$593K$662K$901K$203K
Net income-$2.48M-$14.27M-$9.86M-$1.37M$1.93M-$2.24M$3.73M$569K
Net income attributable to common shareholders-$4.05M-$11.66M-$8.69M-$1.72M$1.03M-$2.04M$2.7M-$99K
EBITDA-$1.05M-$12.88M-$8.68M$815K$2.32M-$1.23M$2.81M$1.16M
Basic earnings per share-$0.04-$0.12-$0.10-$0.02$0.01-$0.02$0.03$0.00
Diluted earnings per share-$0.04-$0.12-$0.10-$0.01$0.01-$0.03$0.03$0.00

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Gyre Therapeutics, Inc. (GYRE) Tops Q3 Earnings and Revenue Estimates

Gyre Therapeutics reported Q3 2026 earnings of $0.04 per share, beating consensus estimates of a $0.15 loss, with revenues of $32.93 million exceeding expectations by 15.15%. However, the stock has declined 37.1% year-to-date versus the S&P 500's 12.3% gain. The company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

Benzinga

Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company

Gyre Therapeutics has completed its all-stock acquisition of Cullgen Inc. for approximately $300 million, creating a fully integrated biopharmaceutical company with U.S. and China operations. The combined entity will have a commercial-stage product (ETUARY® for lung fibrosis) and a robust pipeline focused on fibrosis and inflammatory diseases, including the lead candidate F351 for liver fibrosis. Dr. Ying Luo, former CEO of Cullgen, becomes President and CEO of the combined company.

GlobeNewswire Inc.

Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Gyre Therapeutics reported full-year 2025 revenue of $116.6 million, up 10% year-over-year, within guidance. The company achieved alignment with China's CDE on conditional approval pathway for Hydronidone with NDA submission expected in H1 2026. Gyre completed enrollment in a Phase 3 pirfenidone pneumoconiosis trial and announced an agreement to acquire Cullgen for approximately $300 million to expand its targeted protein degradation platform. However, 2026 revenue guidance of $100.5-$111.0 million represents a 4.8-13.8% decline, reflecting a transition period prioritizing regulatory activities.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Jan 13, 2023$0.24Jan 12, 2023special
Sep 21, 2022$0.715Sep 20, 2022special
Aug 20, 2015$4.269Aug 19, 2015special

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jan 13, 20232-for-1stock dividend
Feb 13, 20171-for-15reverse split